Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy

Immunology and Cell Biology

Volumn 91, Issue 5, 2013, Pages 360-367

  Wang, Wei ^a,b   He, Wen ^a,c,d   Wang, Lei ^a,d   Zhang, Ge ^a,d   Gao, Bin ^a,b,d  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

combody; death receptor; multivalent antibody; scFv; TRAIL

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; DEATH RECEPTOR 5; MONOMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING KINETICS; CELL VIABILITY; CHEMICAL REACTION; CONTROLLED STUDY; CYTOMETRY; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OENTAMERIZATION; SURFACE PLASMON RESONANCE; TUMOR CELL LINE; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTIBODY AFFINITY; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG DESIGN; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; POLYMERIZATION; PROTEIN ENGINEERING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878565584     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.10     Document Type: Article

References (42)

1. Nelson AL. Antibody fragments: hope and hype. MAbs 2010; 2, 77-83
2. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 1999; 453, 164-168
3. Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Pluckthun A. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 2006; 281, 35186-35201.
4. Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng 2001; 14, 1025-1033
5. Weber-Bornhauser S, Eggenberger J, Jelesarov I, Bernard A, Berger C, Bosshard HR. Thermodynamics and kinetics of the reaction of a single-chain antibody fragment (scFv) with the leucine zipper domain of transcription factor GCN4. Biochemistry 1998; 37, 13011-13020.
6. Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C et al. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. MAbs 2010; 2, 20-34.
7. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3, 673-682
8. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276, 111-113
9. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277, 815-818
10. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N et al. TRAILR2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16, 5386-5397
11. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6, 564-567
12. Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39, 633-640.
13. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7, 383-385
14. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28, 2839-2846
15. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-smallcell lung cancer. J Clin Oncol 2010; 28, 1527-1533
16. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29, 4442-4451
17. Camidge D, Herbst RS, Gordon M, Eckhardt S, Kurzroc R, Durbin B et al. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J Clin Oncol 2007; 25, 3582.
18. Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N et al. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68, 733-741
19. Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010; 25, 13-19
20. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM et al. A phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Brit J Cancer 2010; 103, 1783-1787.
21. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Brit J Cancer 2010; 102, 506-512
22. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13, 6187-6194
23. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Anna Oncol 2010; 21, 376-381.
24. Sharma S, EGd Vries, Infante JR, Oldenhuis C, Chiang L, Bilic S et al. Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. J Clin Oncol 2008; 26, 3538.
25. Zhu X, Wang L, Liu R, Flutter B, Li S, Ding J et al. COMBODY: one-domain antibody multimer with improved avidity. Immunol Cell Biol 2010; 88, 667-675
26. Pack P, Muller K, Zahn R, Pluckthun A. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J Mol Biol 1995; 246, 28-34
27. Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H et al. Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol 2004; 335, 49-56
28. Terskikh AV, Le Doussal JM, Crameri R, Fisch I, Mach JP, Kajava AV. 'Peptabody': a new type of high avidity binding protein. Proc Natl Acad Sci USA 1997; 94, 1663-1668
29. Efimov VP, Engel J, Malashkevich VN. Crystallization and preliminary crystallographic study of the pentamerizing domain from cartilage oligomeric matrix protein: a fivestranded alpha-helical bundle. Proteins 1996; 24, 259-262.
30. Thie H, Binius S, Schirrmann T, Hust M, Dubel S. Multimerization domains for antibody phage display and antibody production. N Biotechnol 2009; 26, 314-321
31. Gerstner RB, Carter P, Lowman HB. Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody. J Mol Biol 2002; 321, 851-862
32. Lee SH, Park DW, Sung ES, Park HR, Kim JK, Kim YS. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity. Mol Immunol 2010; 47, 816-824
33. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26, 7046-7055
34. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 2001; 98, 13884-13888
35. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 2002; 21, 4520-4530
36. Park KJ, Lee SH, Kim TI, Lee HW, Lee CH, Kim EH et al. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res 2007; 67, 7327-7334.
37. Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase- independent cell death. J Biol Chem 2005; 280, 41940-41952.
38. Chen F, Guo J, Zhang Y, Zhao Y, Zhou N, Liu S et al. Knockdown of c-FLIP(L) enhanced AD5-10 anti-death receptor 5 monoclonal antibody-induced apoptosis in human lung cancer cells. Cancer Sci 2009; 100, 940-947
39. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7, 1001-1012
40. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15, 751-761.
41. Park KJ, Lee SH, Lee CH, Jang JY, Chung J, Kwon MH et al. Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. Biochem Bioph Res Co 2009; 382, 726-729.
42. Schofield DJ, Pope AR, Clementel V, Buckell J, Chapple S, Clarke KF et al. Application of phage display to high throughput antibody generation and characterization. Genome Biol 2007; 8, R254